U.S. markets open in 8 hours 33 minutes

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytomX Therapeutics, Inc. - CTMX

NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CytomX Therapeutics, Inc. (“CytomX” or the “Company”) (NASDAQ: CTMX).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether CytomX and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 13, 2020, CytomX made available abstracts for the Company’s clinical presentations for CX-072, an PD-L1 inhibitor, and CX-2009, an antibody-drug conjugate.  Results from CytomX’s Phase 2 study evaluating CX-072 in patients with solid tumors showed a response rate of 8.8%, compared to a response rate of 18.5% in patients receiving the combination of CX-072 and Bristol Myers Squibb’s Yervoy (ipilimumab).  Meanwhile, results from CytomX’s Phase 1/2 study evaluating CX-2009 in patients with solid tumors showed “evidence” of clinical activity at doses at least 4 mg/kg 3x/week, yet the data suggest a significantly higher rate of serious or greater treatment-related toxicity to the eyes at dose equivalents at least 8 mg/kg 3x/week.  Following the release of the foregoing data, CytomX’s stock price fell sharply during intraday trading on May 14, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 9980